Market Place
Sourcing Support
Hepion Pharmaceuticals Completes OTCQB Application
25 Jun 2025 //
GLOBENEWSWIRE
Hepion Pharmaceuticals Names Dr. Kaouthar Lbiati Interim CEO
16 Jun 2025 //
GLOBENEWSWIRE
Hepion Pharmaceuticals Receives Delisting Notification from Nasdaq
12 May 2025 //
GLOBENEWSWIRE
Hepion Pharmaceuticals Announces Reverse Stock Split
14 Mar 2025 //
GLOBENEWSWIRE
Hepion Pharmaceuticals Announces $9.0 Million Public Offering
22 Jan 2025 //
GLOBENEWSWIRE
Hepion Pharma Terminates Merger with Pharma Two B Ltd.
11 Dec 2024 //
GLOBENEWSWIRE
Pharma Two B & Hepion Announce Merger Registration Effectiveness
11 Nov 2024 //
GLOBENEWSWIRE
In struggling Hepion spies path to go public before seeking FDA approval
22 Jul 2024 //
FIERCE BIOTECH
Pharma Two B To Merge With Hepion And Raise $11.5M In Placement
22 Jul 2024 //
GLOBENEWSWIRE
Why Is Liver-Disease Drug Developer Hepion Stock Trading Lower On Monday?
23 Apr 2024 //
YAHOO
Hepion Initiates Wind-Down Activities in Phase 2b ˜ASCEND-NASH™ Trial
19 Apr 2024 //
GLOBENEWSWIRE
Hepion Strengthens Board of Directors with Appointment of Michael Purcell
06 Mar 2024 //
GLOBENEWSWIRE
Hepion Announces Exercise of Warrants for $2.0M Aggregate Gross Proceeds
16 Feb 2024 //
GLOBENEWSWIRE
Hepion Pharmaceuticals to Present at NASH-TAG 2024
03 Jan 2024 //
GLOBENEWSWIRE
Hepion Pharmaceuticals Announces Restructuring Plan
07 Dec 2023 //
GLOBENEWSWIRE
NASH drugmaker Hepion to seek strategic alternatives
07 Dec 2023 //
ENDPTS
Hepion’s NASH trial hangs in balance amid cost-cutting, CEO exit
07 Dec 2023 //
FIERCE BIOTECH
Hepion Pharma to Present at the 7th Obesity & NASH Drug Development Summit
28 Nov 2023 //
GLOBENEWSWIRE
Hepion Pharmaceuticals Schedules Conference Call
10 Nov 2023 //
GLOBENEWSWIRE
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering
29 Sep 2023 //
GLOBENEWSWIRE
Hepion Pharma to Participate in 2023 Cantor Global Healthcare Conference
21 Sep 2023 //
GLOBENEWSWIRE
Hepion Pharmaceuticals Announces Management Changes
06 Sep 2023 //
GLOBENEWSWIRE
Hepion Announces Passing of Key Safety Milestone in Phase 2b ASCEND-NASH™
15 Jun 2023 //
GLOBENEWSWIRE
Hepion Pharmaceuticals to Present Two Posters at EASL International
15 Jun 2023 //
GLOBENEWSWIRE
Hepion Pharmaceuticals to Highlight AI-POWR at the 2023 CSPS Annual Symposium
24 May 2023 //
GLOBENEWSWIRE
Hepion shares midphase NASH data ahead of key clinical readout
22 May 2023 //
FIERCE BIOTECH
Hepion Schedules Conference to Review Results from Trial of Rencofilstat
19 May 2023 //
GLOBENEWSWIRE
Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split
10 May 2023 //
GLOBENEWSWIRE
Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLs
30 Mar 2023 //
GLOBENEWSWIRE
Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development
16 Mar 2023 //
GLOBENEWSWIRE
Hepion to Deliver Updates on Phase 2 NASH Clinical Program with Rencofilstat
02 Mar 2023 //
GLOBENEWSWIRE
Hepion to Ring the NASDAQ Stock Market Closing Bell on February 10, 2023
09 Feb 2023 //
GLOBENEWSWIRE
Hepion Pharmaceuticals Receives $3.2 Million in Aggregate Non-Dilutive Funding
09 Jan 2023 //
GLOBENEWSWIRE
Hepion Pharmaceuticals Announces Early Completion of Enrollment in Ph2
05 Dec 2022 //
GLOBENEWSWIRE
Hepion Pharma Granted 180-day Extension by Nasdaq to Meet the Minimum Bid Price
05 Dec 2022 //
GLOBENEWSWIRE
Hepion Pharmaceuticals to Present Rencofilstat’s Poly-Indication Potential
07 Nov 2022 //
GLOBENEWSWIRE
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private
04 Nov 2022 //
GLOBENEWSWIRE
Hepion to Present Two Posters at Upcoming AASLD The Liver Meeting 2022
02 Nov 2022 //
GLOBENEWSWIRE
Hepion Announces Publication of Phase 2a ‘AMBITION’ Clinical Trial Results
26 Oct 2022 //
GLOBENEWSWIRE
Hepion Pharma Announces Publication of Food Effect Study with Rencofilstat
20 Oct 2022 //
GLOBENEWSWIRE
Hepion Pharmaceuticals to Participate in the ThinkEquity Conference
19 Oct 2022 //
GLOBENEWSWIRE
Hepion Pharmaceuticals to Participate in Cantor Oncology, Hematology & HemeOnc
26 Sep 2022 //
GLOBENEWSWIRE
Hepion Announces Initiation of Dosing in Ph2 ‘ALTITUDE-NASH’ Liver Trial
12 Sep 2022 //
GLOBENEWSWIRE
Hepion Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual GHC
08 Sep 2022 //
GLOBENEWSWIRE
Hepion screens first subject in Phase IIb trial of NASH drug
01 Sep 2022 //
CLINICALTRIALSARENA
Hepion Pharmaceuticals Announces Initiation of Phase 2b ‘ASCEND-NASH’ Trial
31 Aug 2022 //
GLOBENEWSWIRE
Hepion Pharma Announces Further Adjournment of Annual Meeting of Stockholders
22 Jul 2022 //
GLOBENEWSWIRE
Hepion Pharma Strengthens Board with Appointments of Accomplished Executives
28 Jun 2022 //
GLOBENEWSWIRE
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders
24 Jun 2022 //
GLOBENEWSWIRE
Hepion Pharma Bags FDA ODD stautus for Rencofilstat in Hepatocellular Carcinoma
20 Jun 2022 //
GLOBENEWSWIRE
Hepion Pharma to Present Five Posters at EASL 2022
15 Jun 2022 //
GLOBENEWSWIRE
Hepion Pharma Appoints Industry Veteran, Dr. Launa J. Aspeslet, as COO
14 Jun 2022 //
GLOBENEWSWIRE
Hepion Pharma Urges Shareholders to Vote "FOR"All Proposals
31 May 2022 //
GLOBENEWSWIRE
Hepion Pharma Highlights Upcoming PII Trials of Recofilstat at 5th NASH Congress
27 May 2022 //
GLOBENEWSWIRE
CORRECTING and REPLACING - Hepion Pharmaceuticals, Inc.
27 May 2022 //
GLOBENEWSWIRE
Hepion Pharma to Present at the Q1 Investor Summit Conference
07 Mar 2022 //
GLOBENEWSWIRE
Hepion`s Rencofilstat with ICI Demonstrates Synergistic Anti-Tumor Activity
26 Jan 2022 //
GLOBENEWSWIRE
Hepion`s USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431
06 Jan 2022 //
GLOBENEWSWIRE
Hepion Announces FDA Clearance of IND Application for CRV431 in Liver Cancer
21 Dec 2021 //
GLOBENEWSWIRE
Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431
16 Nov 2021 //
GLOBENEWSWIRE
